Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy.
We present a case of metastatic non-small-cell lung malignancy diagnosed in the mother in her 24th week of pregnancy and illustrate the obstetric, oncology, neonatal and ethical issues involved. This is the second reported case on the use of gemcitabine for lung cancer in human pregnancy.
Gurumurthy
M
M
Department of Obstetrics and Gynaecology, Arden Cancer Centre and Neonatal Unit, University Hospital Coventry and Warwickshire, Coventry, UK. m.gurumurthy@nhs.net
Koh
P
P
Singh
R
R
Bhide
A
A
Satodia
P
P
Hocking
M
M
Anbarasu
A
A
Wood
L E P
LE
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy* / Q000556:secondary; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000209:etiology*; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine